Close Menu

phase I clinical study

Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.

A Start

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

In the Phase I/IB study, only patients with NTRK or ROS1 fusions, or an ALK fusion or mutation responded to entrectinib, while patients without these tumor markers didn’t respond.

The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.

Quark Pharmaceuticals last week announced “favorable” interim results from a phase I trial of its siRNA-based ocular neuroprotectant QPI-1007, showing the drug may improve the vision of patients with a rare eye condition.

Alnylam partner Tekmira Pharmaceuticals said it views the data as a validation of its drug-delivery technology, which will be used in two new oncology programs it unveiled this week.

The disclosure comes almost a year after Calando Pharmaceuticals published phase I data demonstrating that its own cancer drug CALAA-01 could knock down its intended target mRNA and protein inside a tumor through an RNA interference mechanism when delivered intravenously into humans.

The phase I drug, ALN-VSP02, comprises two siRNAs, one targeting vascular endothelial growth factor and one targeting kinesin spindle protein, both of which the firm said are critical for the growth and survival of cancer cells.

The data, which appeared in the online edition of Nature, "demonstrate that RNAi can occur in a human from a systemically delivered siRNA, and that siRNA can be used as a gene-specific therapeutic," the investigators wrote.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.